• Publications
  • Influence
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Daily tesamorelin for 26 weeks decreased visceral fat and improved lipid profiles, effects that might be useful in HIV-infected patients who have treatment-associated central fat accumulation.
Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader–Willi syndrome
The switch to excessive weight gain in PWS seems to coincide with an increase in the AG/UAG ratio, even prior to the start of hyperphagia, as PWS had a high AG and obese a very low UAG.
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Treatment with tesamorelin was generally well tolerated and resulted in sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose, though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment.
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
TH9507 reduced truncal fat, improved the lipid profile and did not increase glucose levels in HIV-infected patients with central fat accumulation and longer-term studies with more patients are needed to determine effects on VAT, treatment durability, and safety.
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP‐531, a first‐in‐class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes
To explore the safety, pharmacokinetics and pharmacodynamics in humans of the unacylated ghrelin analogue AZP‐531, designed to improve glycaemic control and reduce weight.
Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines
It is shown that, for B-ALL cell lines, changes in the expression of apoptosis-regulatory genes (especially NFκB-related genes) are associated with ASNase susceptibility, suggesting that according to cellular context, factors other than AsnS can influence ASnase susceptibility.
In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues.
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
AZP-531 may constitute a new treatment strategy to improve hyperphagia and metabolic issues in patients with Prader-Willi syndrome and support further investigation in longer-term clinical trials.
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase
PEG-r-crisantaspase appears to be a promising drug candidate for ALL treatment and should be further explored in experimental and clinical trials.
Unacylated ghrelin analog prevents myocardial reperfusion injury independently of permeability transition pore
Treatment with AZP-531 rescued the myocardium from cell death at early reperfusion by stimulating protein synthesis, inhibiting Bax/caspase 3-induced apoptosis as well as ROS accumulation and oxidative stress-induced necrosis and may prove useful in the treatment of IR injury.